Second generation patents in pharmaceutical innovation

The development of new medications and improvements thereof are crucial to ensure continued gains in health. The development process is long and costly, and mainly to produce the information to meet high regulatory requirements. In contrast, imitation involves negligible costs and much reduced risks...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Ahn, Hyewon
Format: E-Book Buch Verlag
Sprache:Englisch
Veröffentlicht: Baden-Baden Nomos 2014
Nomos Verlagsgesellschaft mbH & Co. KG
Nomos Verlagsgesellschaft
Ausgabe:1
Schriftenreihe:Munich Intellectual Property Law Center – MIPLC
Schlagworte:
Book Industry Communication
Commercial
Drug development
Drug development. fast (OCoLC)fst00898670
Drugs > Law and legislation
Drugs > Law and legislation. fast (OCoLC)fst00898830
Drugs > Patents
Drugs. fast (OCoLC)fst00898761
Economic aspects
Gewerblicher Rechtsschutz
K1-7720
Law
Markenrecht
Patent laws and legislation
Patent laws and legislation. fast (OCoLC)fst01054823
Patents. fast (OCoLC)fst01423842
Pharmaceutical industry
Pharmaceutical policy
Technological innovations
Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht
ISBN:3848708744, 9783848708741, 9783845250861, 3845250860
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The development of new medications and improvements thereof are crucial to ensure continued gains in health. The development process is long and costly, and mainly to produce the information to meet high regulatory requirements. In contrast, imitation involves negligible costs and much reduced risks. This is one of the reasons the pharmaceutical industry depends greatly on patent protection. Despite the existing patent system, however, the number of new medications per year has decreased, especially during the last decade. In comparison, the number of second generation patents and products has been drastically increased. This industry is accused both of neglecting its real mission of providing new medications while generating second generation products, and of preventing the entry of generics. The dissertation reviewed whether the concerns are justified, and, if so, whether or how the patent system can improve the situation that confronts pharmaceutical companies and society.
Bibliographie:Includes bibliographical references (p. 333-354)
MODID-ff01a8158bb:Nomos
ISBN:3848708744
9783848708741
9783845250861
3845250860
DOI:10.5771/9783845250861